Meeting
2016 ASCO Annual Meeting
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
Authors
Wolfgang Wick
Neurology Clinic, Heidelberg, Germany
Wolfgang Wick , Roger Stupp , Thierry Gorlia , Martin Bendszus , Felix Sahm , Jacoline E Bromberg , Alba Ariela Brandes , Maaike J Vos , Julien Domont , Ahmed Idbaih , Jean-Sebastien Frenel , Paul M. Clement , Michel Fabbro , Emilie Le Rhun , François Dubois , Davide Musmeci , Michael Platten , Vassilis Golfinopoulos , Martin J. Van Den Bent
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01290939
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2019)
DOI
10.1200/JCO.2016.34.15_suppl.2019
Abstract #
2019
Poster Bd #
208
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET).
First Author: Kathryn Maree Field
Poster
2016 ASCO Annual Meeting
Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma.
First Author: Johnny Duerinck
Poster
2016 ASCO Annual Meeting
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
First Author: Martin J. Van Den Bent
Poster
2015 ASCO Annual Meeting
A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma.
First Author: Alba Ariela Brandes